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Abstract
Background: HIV-1 subtype C Nef sequences have a significantly lower ability overall to down-regulate CD4
and HLA-I than subtype B Nef sequences. Here we investigated whether Nef amino acids differing in frequency
between HIV-1 subtypes B and C explain lower CD4 and HLA-I down-regulation ability of subtype C.
Findings: Subtype-specific mutations were introduced into representative subtype B and C Nef sequences and the
CD4 and HLA-I down-regulation ability of these mutants was measured by flow cytometry in a CD4+ T cell line.
Subtype C consensus 20I and subtype B consensus 20M reduced and increased HLA-I down-regulation respectively,
and the S88G immune escape mutation (which is significantly more frequent in subtype C than subtype B) reduced
CD4 and HLA-I down-regulation.
Conclusions: Our data suggest that these subtype-specific differences may partly contribute to inter-subtype
functional differences, and identification of an immune escape mutation – S88G – that impairs Nef function is of
relevance to vaccine design.
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The HIV-1 accessory protein Nef enhances viral replica-
tion and is critical for in vivo pathogenesis [1]. Infection
with Nef-deleted HIV-1 strains is associated with long-
term non-progression to AIDS, low plasma viral loads
and maintenance of normal CD4 counts [2, 3]. Nef
performs numerous activities that may contribute to its
pathogenic effect, including the down-regulation of CD4
and HLA class I (HLA-I) molecules from the surface of
infected cells. Down-regulation of CD4 promotes the
budding of virions from infected cells thereby increasing
viral replication, while down-regulation of HLA-I allows
infected cells to evade recognition by cytotoxic T cells.
Recently, we reported that the CD4 and HLA-I down-
regulation abilities of patient-derived Nef clones differed
significantly between subtype A, B, C and D isolates;
with subtype B clones displaying the highest CD4 and
HLA-I down-regulation activity and subtype C clones
displaying the lowest activity [4]. However, the mecha-
nisms underlying these functional differences between
subtypes remain unknown. A comparison of subtype B
and C Nef sequences revealed that the consensus amino
acids at codons 20, 35 and 59 differed between subtype
B (encoding M, R and E, respectively) and subtype C
(I, Q and Q, respectively) [4], and these three codons
were reported to be involved in CD4 or HLA-I
down-regulation by Nef [5–7]. Specifically, introduc-
tion of alanine or arginine at codon 20 resulted in
significant loss of HLA-I down-regulation activity [7],
mutation of residues 35 and 36 to alanine impaired
CD4 down-regulation ability [5] and codon 59 is part
of the CD4 binding site of Nef [5, 6]. Thus, these are
candidate residues for mediating Nef functional dif-
ferences between subtypes B and C. To identify add-
itional Nef residues and naturally occurring amino
acid variations that could potentially contribute to
functional differences between subtypes, we examined
statistical associations (not yet confirmed experimen-
tally) between amino acid polymorphisms and altered
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down-regulation ability by patient-derived Nef sequences
[4], and then compared the frequency of these amino acids
between subtypes. Differences in the frequency of amino
acids at Nef codons 8, 9, 11, 14 and 88 between subtypes
coincided with the functional hierarchy observed among
viral subtypes [4]. Specifically, consensus amino acids 8S,
9S, 11 V and 14P (which were the consensus residues for
all four subtypes) were statistically associated with lower
HLA-I down-regulation ability and were significantly less
frequent in subtype B, which displayed the highest HLA-I
down-regulation ability. Furthermore, the mutation S88G
was statistically associated with lower CD4 down-
regulation and was more frequent in subtype C, which
displayed the lowest CD4 down-regulation ability.
Therefore, we hypothesised that residues 8–14 and 88
might also contribute to observed functional differences
between subtypes B and C.
In the present study, we directly assessed the effect of
subtype-specific mutations at these Nef codons of inter-
est on CD4 and HLA-I down-regulation ability in order
to investigate whether these sequence variations contrib-
ute to the inter-subtype differences in Nef function. The
list of mutations tested is shown in Table 1. Mutations
were introduced into a subtype B Nef sequence, derived
from the laboratory-adapted HIV-1 NL4-3 reference strain
(which was first mutated to the subtype B consensus resi-
due valine at codon 11 since the wild-type contains isoleu-
cine at this position), as well as a patient-derived subtype
C Nef sequence (SK68, called C13 in our prior study;
Genbank accession KC906737), the Nef sequence from
those described in [4] that had both the consensus
residues at the codons of interest and the highest similar-
ity to the consensus C sequence. In addition, mutations at
codons 8–14 naturally present in a patient-derived
subtype B Nef sequence (B47; Genbank accession
KC906941) were reverted to consensus B residues to
assess their impact on Nef function. Figure 1 shows the
first 100 residues of Nef sequences NL4-3, SK68 and B47
relative to consensus B and C sequences [4] and highlights
sites of mutation. Mutations were introduced into the Nef
sequences by site-directed mutagenesis [8] using the
QuikChange II XL Site-Directed Mutagenesis kit (Strata-
gene, USA), according to the manufacturer’s instructions.
The CD4 and HLA-I down-regulation activities of the
mutant Nef sequences were measured as previously
described [4]. Briefly, the Nef sequences were cloned
into a green fluorescent protein (GFP) reporter expres-
sion plasmid. Mutant Nef clones were then electropo-
rated into a CEM-derived CD4 T cell line engineered to
express high levels of HLA-A*02. Cell surface levels of
CD4 and HLA-A*02 were measured using fluorescently-
labelled antibodies specific for these molecules and flow
cytometry. The median fluorescent intensity (MFI) of
CD4 or HLA-A*02 in cells successfully transfected with
Nef clones (GFP-expressing cells) was first expressed
relative to the MFI of the SF2 Nef positive control and
the empty plasmid negative control included in each ex-
periment by the following equation: (negative control –
Nef clone)/(negative control – positive control), where a
value of 0 indicates no down-regulation activity and a
value of 1 indicates down-regulation activity equivalent
to SF2. Then, for comparison of mutant and wild-type
clones, the CD4 and HLA down-regulation values for all
mutant Nef clones were expressed as a percentage of the
relevant wild-type (NL4-3, SK68 or B47) such that the
wild-type represented 100 % down-regulation activity.
Experiments were performed at least in triplicate and
results averaged. For mutants that differed by more than
10 % in function from the wild-type, T tests with a
p value cut-off of 0.05 were performed to test for signifi-
cant difference from the wild-type.
Representative flow cytometry plots of the assay con-
trols – empty plasmid negative control (showing no
down-regulation activity) and SF2 Nef positive control
(showing efficient down-regulation activity) – are shown
in Fig. 2. We previously observed that differences in
Nef-mediated CD4 and HLA-I down-regulation between
consensus B and C Nef sequences were more apparent
in cells expressing lower levels of Nef protein [4]. Since
CD4 down-regulation function is highly conserved (our
previous measurements for this function showed a very
narrow spread of values across different Nef clones) we
analysed CD4 down-regulation activity based on all
GFP-expressing cells as well as the lower third of GFP-
expressing cells only. Results were consistent for both
gating strategies but differences in CD4 down-regulation
between mutants were slightly greater (and therefore
more clearly observed) in cells expressing lower levels of
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Fig. 1 Subtype B and C Nef sequences and sites of mutation. The first 100 codons of the subtype B Nef sequences (NL4-3 and B47) and the
subtype C Nef sequence (SK68) into which mutations were introduced are shown relative to the consensus B (Con_B) and consensus C (Con_C)
Nef sequences. Sequences were aligned to HXB2 (and the subtype C specific insertion in the 62EEEE65 motif with respect to HXB2 was stripped
out). Codons at which mutations were introduced are shown in bold. It should be noted that, prior to commencing experiments, the NL4-3 Nef
sequence was mutated to the subtype B consensus residue valine at codon 11 since the wild-type contains isoleucine
Fig. 2 Representative flow cytometry plots of assay controls and Nef expression. Plots show cell-surface expression of CD4 or HLA-I (y axis) in
cells transfected with empty plasmid (Δ Nef, negative control) and plasmid expressing SF2 Nef (positive control). Green fluorescent protein (GFP)
expression is shown on the x axis and is an indicator of cells successfully transfected with plasmids. CD4 expression was measured in the lower
third of GFP-expressing cells and HLA-I expression was measured in all GFP-expressing cells (gates shown on plots)
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the Nef protein, therefore these results are presented
here. Replicate measurements for both Nef functions
were in excellent agreement (Pearson’s correlation r ≥
0.94 and p < 0.0001) as shown previously using this
method [4].
At the codons that were previously reported to be
involved in CD4/HLA-I down-regulation and where the
consensus amino acids differed between subtypes B and
C, namely codons 20, 35 and 59, the subtype B Nef
(NL4-3) was mutated to the subtype C consensus resi-
due (20I, 35Q, and 59Q) and the subtype C Nef (SK68)
was mutated to the subtype B consensus residue (20 M,
35R, and 59E). It was hypothesised that the subtype C
consensus residues would decrease the down-regulation
ability of NL4-3 and that the subtype B consensus
residues would increase the down-regulation ability of
SK68. As predicted, NL4-3 M20I displayed significantly
reduced HLA-I down-regulation ability (to 69 % of wild-
type levels, p < 0.0001, Fig. 3a) while HLA-I down-
regulation ability was significantly increased in SK68 by
the I20M mutation (to 118 % of wild-type levels, p =
0.0087, Fig. 3b), indicating that subtype-specific differ-
ences at codon 20 may contribute to the lower HLA-I
down-regulation ability of subtype C Nefs relative to
subtype B Nefs. Consistent with this, we recently re-
ported that I20M was statistically associated with
higher HLA-I down-regulation in 298 subtype C patient-
derived Nef sequences [9]. However, a recent report
suggested that M20I modestly enhanced the HLA-I
down-regulation function of the subtype B Nef se-
quence SF2 [10], suggesting that other polymorphisms
in Nef can modulate the effect of codon 20. Additional
studies will be necessary to elucidate this. Nevertheless,
our results support the conclusion that subtype-specific
Fig. 3 CD4 and HLA-I down-regulation ability of Nefs mutated to subtype B and C consensus residues. The HLA-I down-regulation ability of the
subtype B NL4-3 Nef mutated to subtype C consensus residues 20I, 35Q and 59Q (panel a) and the subtype C SK68 Nef mutated to subtype B
consensus residues 20 M, 35R and 59E (panel b) is shown. Similarly the CD4 down-regulation ability of these mutants is shown in panels c and d.
Down-regulation activity is expressed relative to the respective wild-type protein (NL4-3 or SK68), which represents 100 %. The CD4 and HLA-I
down-regulation ability expressed relative to SF2 was 97 and 99 % respectively for NL4-3, and 89 and 69 % respectively for SK68. Bars represent
the mean of at least 3 replicates, and error bars represent standard deviations from the means. Asterisks indicate mutant clones that were > 10 %
different in function from the wild-type and were significantly different from the wild-type as indicated by the Student’s T test (p < 0.05)
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residues at codon 20 can affect HLA-I down-regulation
ability and that this may partly explain inter-subtype differ-
ences in this Nef function. On the other hand, we observed
that subtype-specific mutations at codons 35 and 59 (in
regions previously described to be involved in CD4 down-
regulation [5, 6]) did not appreciably affect CD4 down-
regulation ability of NL4-3 (Fig. 3c) or SK68 (Fig. 3d).
Thus, we found no evidence that subtype-specific differ-
ences at these codons contribute to differences in this Nef
function between subtypes B and C.
The S88G mutation was statistically associated with
reduced CD4 down-regulation ability in patient-derived
subtype C Nef sequences in our prior study [4]. To dir-
ectly test whether the S88G mutation decreases CD4
down-regulation ability, this mutation was introduced
into both NL4-3 and SK68. Furthermore, we found that
the S88G mutation seldom occurred in the absence of
the co-varying mutation E98D (considering subtype C
sequences reported in [4], 81 % of sequences encoding
S88G also harboured E98D), therefore the functional ef-
fect of these mutations alone as well as in combination
was tested. Consistent with our hypothesis based on
statistical associations, we observed that the S88G muta-
tion significantly reduced CD4 down-regulation ability
of NL4-3 (to 79 % of wild-type levels, p < 0.0001, Fig. 4a)
and SK68 (to 53 % of wild-type levels, p < 0.0001, Fig. 4b).
Interestingly, S88G was also observed to negatively affect
HLA-I down-regulation activity of both Nefs (p < 0.0001
for both, Fig. 4c and d). As expected, when S88G was
present together with E98D down-regulation activity was
higher than when S88G was present alone, indicating
that E98D functions as a compensatory mutation. How-
ever, E98D did not fully restore CD4 or HLA-I down-
regulation function to wild-type levels in SK68 Nef
Fig. 4 CD4 and HLA-I down-regulation ability of Nefs encoding escape and co-varying mutations. The CD4 down-regulation ability of the subtype
B NL4-3 Nef (panel a) and the subtype C SK68 Nef (panel b) encoding the S88G mutation as well as S88G accompanied by the co-varying E98D
mutation is shown. Similarly the HLA-I down-regulation ability of these mutants is shown in panels c and d. Down-regulation activity is expressed
relative to the respective wild-type protein (NL4-3 or SK68), which represents 100 %. The CD4 and HLA-I down-regulation ability expressed relative
to SF2 was 97 and 99 % respectively for NL4-3, and 89 and 69 % respectively for SK68. Bars represent the mean of at least 3 replicates, and error
bars represent standard deviations from the means. Asterisks indicate mutant clones that were > 10 % different in function from the wild-type
and were significantly different from the wild-type as indicated by the Student’s T test (p < 0.05)
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sequences harbouring the S88G mutation (p = 0.0002
and p = 0.0004, respectively), and the NL4-3 S88G/E98D
double mutant remained impaired for HLA-I down-
regulation activity (p < 0.0001), indicating that E98D only
partially compensated for the loss of function associated
with S88G. Since the S88G mutation occurs more
frequently in subtype C Nef sequences than subtype B
Nef sequences, these results suggest that it may contrib-
ute to the overall lower CD4 down-regulation and
HLA-I down-regulation activity observed for subtype C.
Interestingly, S88G is an escape variant selected by
CD8+ T cell responses targeting the HLA-B*58:01-
restricted KF9 epitope [11]. Whether selection of Nef
S88G contributes to the protective effect seen for HLA-
B*58:01 should be examined in future studies. Regard-
less, the identification of such viral escape mutations with
functional costs is informative for an attenuation-based
HIV vaccine strategy [12]. For such a vaccine strategy,
targeting multiple regions of the virus where escape
has a fitness/functional cost may result in delayed im-
mune escape (due to the consequent fitness cost) or
viral attenuation following the development of escape
mutations and consequently an attenuated disease
course.
Fig. 5 CD4 and HLA-I down-regulation ability of Nefs encoding mutations at codons 8-14. The HLA-I down-regulation ability of the subtype B
NL4-3 Nef (panel a) and the subtype C SK68 Nef (panel b) encoding mutations and mutation combinations at codons 8–14 is shown. In addition,
panel a shows the HLA-I down-regulation ability of the subtype B B47 Nef which naturally encoded the 8R/11G/14S mutation combination and
was subsequently mutated to the consensus residues 8S, 11 V and 14P. Similarly the CD4 down-regulation ability of these mutants is shown in
panels c and d. Down-regulation activity is expressed relative to the respective wild-type protein (NL4-3, SK68 or B47), which represents 100 %.
The CD4 and HLA-I down-regulation ability expressed relative to SF2 was 97 and 99 % respectively for NL4-3, 89 and 69 % respectively for SK68,
and 94 and 92 % respectively for B47. Bars represent the mean of at least 3 replicates, and error bars represent standard deviations from the
means. Asterisks indicate mutant clones that were > 10 % different in function from the wild-type and were significantly different from the
wild-type as indicated by the Student’s T test (p < 0.05)
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The most common mutations at codons 8, 9, 11 and
14 were introduced into the subtype B Nef (NL4-3) and
subtype C Nef (SK68) in order to test the hypothesis that
mutations at these codons increase HLA-I down-
regulation activity. Since a deletion was the most common
mutation observed at codon 11 and this was frequently
accompanied by a deletion at codon 10 in subtype B and
C, as well as deletions at codons 9, 10 and 12 in subtype
C, we also studied these combinations. Furthermore, we
observed that mutations at codons 8–14 co-varied and the
patterns of mutations were extremely diverse, therefore
we introduced a pattern observed twice in patient-derived
subtype B Nef sequences – S8L/V10-/V11-/P14A. In both
cases where this pattern occurred there were additional
mutations in close proximity; we selected the S8L/V10-/
V11-/P14A/A15S mutation combination.
We found that mutations at codons 8–14 did not in-
crease HLA-I down-regulation activity of either NL4-3
or SK68 (Fig. 5a and b), and did not appreciably affect
CD4 down-regulation (Fig. 5c and d). Since wild-type
NL4-3 down-regulated HLA-I very well (approximately
equivalent to SF2 Nef in our assays), it was perhaps not
surprising that we did not observe a positive effect of
mutations at codons 8–14 on the HLA-I down-regulation
activity of NL4-3. However, we also reverted a combin-
ation of common mutations at codons 8, 11, 14 – S8R/
V11G/P14S – to the consensus residues in a patient-
derived subtype B sequence (B47) in order to test whether
this would decrease HLA-I down-regulation activity and
we did not observe this effect (Fig. 5a). With the exception
of SK68 S9-/I10-/V11-/G12-, all mutations at codons 8-14
moderately decreased HLA-I down-regulation activity of
SK68, and this was significant for the 9R, 14S, S8L/I10-/
V11-/P14A/A15S and S8R/V11G/P14S mutants (p = 0.034,
p = 0.047, p = 0.0029, and p = 0.0051, respectively, Fig. 5b).
However, it should be noted that except for S9-/I10-/V11-/
G12- the mutation combinations tested were not observed
in subtype C Nef sequences, which may explain this
finding. Overall, we found no evidence that mutations
at codons 8–14 enhance HLA-I down-regulation ac-
tivity and thus contribute to differences in HLA-I
down-regulation activity between subtypes B and C.
Yet, two independent studies have shown statistical
associations between mutations within this region and
increased HLA-I down-regulation activity [4, 13]. In
addition, deletions in this region were previously reported
to associate with weaker selection pressure across Nef
indicating that they are involved in immune escape [14],
which is consistent with our hypothesis that deletions in
this region enhance HLA-I down-regulation. It is possible
that we did not adequately capture the diverse patterns of
mutation in this region, and further experiments may be
required to clarify the role of codons 8–14 in HLA-I
down-regulation.
We reasoned that Nef expression levels may influence
CD4 and HLA-I down-regulation functions and therefore
performed Western blot analysis, as described previously
[4], to explore the impact of mutations on protein expres-
sion levels. Whereas the expression of NL4-3-derived Nef
proteins were quantified, SK68-derived Nef proteins were
undetectable by the antibodies used. NL4-3-derived Nef
mutants M20I, S88G and S88G/E98D were the only mu-
tants that displayed lower expression than the wild-type
(43, 29 and 57 % of wild-type levels, respectively; data not
shown). Interestingly, these were the same mutants that
showed lower HLA-I down-regulation activity (however
only S88G had significantly lower CD4 down-regulation
activity), suggesting that reduced protein expression may
be a mechanism contributing to diminished HLA-I down-
regulation and that Nef expression may influence HLA-I
down-regulation more than CD4 down-regulation.
In summary, we demonstrate here that subtype-specific
differences at Nef codons 20 and 88 significantly affect
this protein’s down-regulation activity. The subtype C
consensus residue 20I reduced HLA-I down-regulation
activity in subtype B and C Nef sequences and S88G,
which is observed more frequently in subtype C Nef se-
quences compared to subtype B sequences, appreciably
reduced CD4 and HLA-I down-regulation activity in Nef
clones from both subtypes. Furthermore, we found that
E98D was able to partially compensate for S88G. Our
findings suggest that subtype-specific differences at these
codons contribute to lower down-regulation activity of
subtype C Nef clones compared to those from subtype B.
Furthermore, the identification of a significant functional
cost associated with the escape mutation S88G may have
implications for vaccine strategies that aim to focus the
immune response on particularly vulnerable regions of the
virus where escape mutations impair protein function.
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